Tri-APBI:3次分割加速部分乳腺照射治疗0-I期乳腺癌的I/II期前瞻性临床试验
单中心前瞻性I/II期试验纳入75例低危激素敏感、HER-2阴性乳腺癌患者,采用HDR近距离治疗(22.5 Gy/3次)或EBRT(25.5 Gy/3次),中位随访49个月。同侧乳腺肿瘤复发累积2.6%,无CTCAE v4.0 2级及以上毒性,美容效果与多数生活质量域未受显著影响。
要点
- 3次分割APBI可行且耐受良好,4年同侧乳腺复发率低(累积2.6%)。
- 未观察到CTCAE v4.0 2级及以上毒性,美容效果定量评估未见乳房不对称加重。
- 48和60个月乳房症状负担及36个月性功能有影响,需进一步长期随访肿瘤学疗效。
核心结论
- Tri-APBI经EBRT或HDR实施可行且耐受良好,4年同侧乳腺肿瘤复发率低,对患者报告生活质量、定性和定量美容效果影响轻微。
研究设计与样本
- 单中心前瞻性I/II期临床试验,2018年8月至2021年3月纳入75例低危激素敏感、HER-2阴性乳腺癌患者。
- HDR近距离治疗为22.5 Gy分3次,EBRT为25.5 Gy分3次,于2至3天内完成,治疗方式由主治医师选择。
- 计划靶区为手术床周围乳腺组织外扩1 cm,距皮肤表面限制为0.5 cm。
主要发现
- I期疾病占79%,其余为导管原位癌;EBRT 44例(59%),HDR 31例(41%)。
- 中位随访49个月(IQR 42-55个月),同侧乳腺肿瘤复发2例,累积2.6%,均成功挽救,无腋窝或远处复发。
- 未观察到CTCAE v4.0 2级及以上毒性。
- 患者与医师评价的良好至优秀美容效果分别为治疗前94%和99%,末次随访91%和98%;pBRA基线均值8.1%(CI 4.1%-12%),24个月均值6.1%(CI 4.0%-8.1%)。
- Tri-APBI未对多数患者报告生活质量域产生负面影响,但48和60个月乳房症状负担及仅36个月性功能受影响。
关键数值与推荐
- HDR剂量22.5 Gy分3次,EBRT剂量25.5 Gy分3次,2至3天内完成。
- 计划靶区为手术床周围乳腺组织外扩1 cm,距皮肤表面限制0.5 cm。
- 同侧乳腺肿瘤复发累积2.6%,中位随访49个月(IQR 42-55个月)。
- 无CTCAE v4.0 2级及以上毒性;pBRA 24个月均值6.1%(CI 4.0%-8.1%)。
临床怎么用
- 对低危激素敏感、HER-2阴性0-I期乳腺癌患者,3次分割APBI(EBRT或HDR)是可行且耐受良好的治疗选择。
- 治疗前应告知患者48和60个月可能出现乳房症状负担、36个月可能出现性功能影响。
- 需长期随访以评估长期肿瘤学疗效。
局限性
- 单中心、样本量75例、非随机,治疗方式由主治医师选择。
- 中位随访49个月,长期肿瘤学疗效尚需进一步随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aims to report safety, feasibility, toxicity, cosmetic, and quality-of-life (QOL) outcomes of a single-institutional prospective phase I/II clinical trial evaluating a novel 3-fraction accelerated partial breast irradiation (Tri-APBI) regimen. METHODS AND MATERIALS: From August 2018 to March 2021, 75 patients with low-risk hormone-sensitive, human epidermal growth factor receptor 2 (HER-2)-negative breast cancer were enrolled on Tri-APBI, delivered with high-dose-rate (HDR) brachytherapy (22.5 Gy in 3 fractions) or external beam radiation therapy (EBRT) (25.5 Gy in 3 fractions) over 2 to 3 days. Modality was chosen by the treating physician. Planning target volume for all patients was created using a 1-cm expansion of breast tissue around the surgical bed, limited by 0.5 cm from the skin surface. RESULTS: Stage I disease was present in 79%, whereas the remainder had ductal carcinoma in situ. Tri-APBI was delivered with EBRT in 44 patients (59%) and HDR in 31 (41%). At a median follow-up of 49 months (IQR, 42-55 months), there were 2 ipsilateral breast tumor recurrences, cumulatively 2.6%, both successfully salvaged. There were no axillary or distant recurrences. There was no Common Terminology Criteria for Adverse Events (CTCAE) v4.0 grade 2+ toxicity observed. Good-to-excellent pretreatment cosmesis was present in 94% and 99% by patient and physician rating, respectively, and in 91% and 98% at the latest follow-up. Quantitative cosmesis assessed by percentage of breast retraction assessment (pBRA) showed that breast asymmetry did not worsen compared with pretreatment, with a baseline mean pBRA of 8.1% (CI, 4.1%-12%) and a 24-month mean pBRA of 6.1% (CI, 4.0%-8.1%). Tri-APBI did not negatively impact most domains of patient-reported QOL, except breast symptom burden at 48 and 60 months and sexual functioning at 36 months only. CONCLUSIONS: Tri-APBI as delivered with EBRT or HDR in this trial was feasible and well-tolerated, with low ipsilateral breast tumor recurrence rates at 4 years and minimal impact on patient-reported QOL, qualitative, and quantitative cosmesis. Further follow-up is needed to evaluate long-term oncologic efficacy.
引用
- Kennedy WR, Raju-Salicki S, Thomas MA, et al. Tri-APBI: Single-Institution Phase I/II Prospective Clinical Trial of 3-Fraction Accelerated Partial Breast Irradiation for Stage 0-I Breast Cancer. Pract Radiat Oncol. 2026. PMID: 42264300. doi:10.1016/j.prro.2026.05.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。